AVBP
NASDAQ · Biotechnology
Arrivent Biopharma Inc
$30.84
-0.17 (-0.55%)
Open$31.57
Previous Close$31.01
Day High$31.79
Day Low$30.27
52W High$35.83
52W Low$16.10
Volume—
Avg Volume454.8K
Market Cap1.44B
P/E Ratio—
EPS$-3.52
SectorBiotechnology
Analyst Ratings
Strong Buy
19 analysts
Price Target
-17.0% upside
Current
$30.84
$30.84
Target
$25.60
$25.60
$15.99
$25.60 avg
$32.44
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 217.05M | 207.22M | 172.47M |
| Net Income | -33,899,494 | -32,015,874 | -32,580,881 |
| Profit Margin | -15.6% | -15.5% | -18.9% |
| EBITDA | -52,835,285 | -48,435,254 | -38,009,184 |
| Free Cash Flow | -36,657,940 | -37,197,569 | -30,385,570 |
| Rev Growth | +1.9% | +19.8% | +13.5% |
| Debt/Equity | 0.28 | 0.20 | 0.23 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |